ClinicalTrialsFinder

Immune-mediated Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials in Sofia

1 recruitingSofia, Bulgaria

Showing 1–1 of 1 trials

Recruiting
Phase 1

A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)

Systemic Lupus Erythematosus (SLE)Alopecia Areata (AA)Immune-mediated Focal Segmental Glomerulosclerosis (FSGS)
Otsuka Pharmaceutical Development & Commercialization, Inc.30 enrolled6 locationsNCT06799520